D'Arena, G., Simeon, V., Laurenti, L., Cimminiello, M., Innocenti, I., Gilio, M., Padula, A., Vigliotti, M. L., De Lorenzo, S., Loseto, G., Passarelli, A., Di Minno, M. N. D., Tucci, M., De Feo, V., D'Auria, F., Silvestris, F., Di Minno, G., & Musto, P. (2017). adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients. Leukemia & lymphoma, 58(11), 2633–2641. http://access.bl.uk/ark:/81055/vdc_100047676210.0x00000d